|| Checking for direct PDF access through Ovid
The Gly482Ser polymorphism in peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PPARGC1A) has been shown to be involved in the pathophysiology of a variety of cardiovascular diseases, however the data on its link with left ventricular (LV) dysfunction are scarce. We sought to investigate the association between the PPARGC1A Gly482Ser polymorphism and LV function in patients with cardiovascular risk factors: hypertension, diabetes and obesity.Methods: We included 120 pts (age 59±10 yrs) with the above entities and a normal stress echo. Each study participant underwent echo study with evaluation of LV systolic (mitral annular systolic velocities – s'sept and s'lat) and diastolic function (mitral inflow parameters, mitral annular early diastolic velocities – e'sept and e'lat) and assessment of the PPARGC1A Gly482Ser polymorphism by PCR method.Results: In patients with the Ser allele (Ser/Ser or Ser/Gly), LV systolic and diastolic function was impaired as compared with their peers with the Gly/Gly genotype (Table). In multivariable analysis, the independent associates of e'sept were: patient age (β=-0.38, p<0.001), diabetes (β= -0.25, p<0.002) and Ser allele (β= -0.19, p<0.02). Correlates of s'sept included age (β=-0.27, p<0.002) and Ser allele (β= -0.20, p<0.02).Conclusions: In patients with cardiovascular risk factors, the PPARGC1A Gly482Ser polymorphism is one of determinants of cardiac performance and the presence of the Ser allele independently contributes to LV systolic and diastolic impairment.